GGrantIndex
← Search

LY231514 &GEMCITABINE EVERY 21 DAYS IN PATIENTS W/ ADVANCED CANCER

$0M01FY2000RRNIH

Mayo Clinic Coll Of Medicine, Rochester, Rochester MN

Investigators

Linked publications & trials

Abstract

LY231514 is a novel multitargeted antifolate drug which has exhibited cytotoxic synergy, when combined sequentially with gemcitabine in cultured human carcinoma cell lines. Gemcitabine is a novel antimetabolite which inhibits DNA synthesis. It is our hypothesis that the combination of LY231514 and gemcitabine is a potent and effective antitumor treatment.

View original record on NIH RePORTER →